Evidence map›Paper›PMID 28817303›Full record

Observational studyJournal of child and adolescent psychopharmacology2017

CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.

Madelyn A Gillentine, Janson J White, Christopher M Grochowski, James R Lupski, Christian P Schaaf, Chadi A Calarge

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of child and adolescent psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Bidirectional Regulation of Aggression in Mice by Hippocampal Alpha-7 Nicotinic Acetylcholine Receptors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Madelyn A Gillentine1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas.
Janson J White1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas.
Christopher M Grochowski1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas.
James R Lupski1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas.
Christian P Schaaf1 Department of Molecular and Human Genetics, Baylor College of Medicine , Houston, Texas.
Chadi A Calarge5 Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine , Houston, Texas.
Baylor College of Medicine · USBaylor Genetics · US

Funding

PROGRAM IN HUMAN MOLECULAR GENETICST32GM008307 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SHAULSKY, GAD · 1990 to 2020
$6.6M
NIGMS NIH HHS T32 GM008307
6 · The paper itself

Abstract

objectiveAggression is among the most common indications for referral to child and adolescent mental health services and is often challenging to treat. Understanding the biological underpinnings of aggression could help optimize treatment efficacy. Neuronal nicotinic acetylcholine receptors (nAChRs), specifically the α7 nAChR, encoded by the gene CHRNA7, have been implicated in aggressive behaviors in animal models as well as humans. Copy number variants (CNVs) of CHRNA7 are found in individuals with neuropsychiatric disorders, often with comorbid aggression. In this study, we aimed to determine the prevalence of CHRNA7 CNVs among individuals treated with risperidone, predominantly for irritability and aggression.

methodsRisperidone-treated children and adolescents were assessed for CHRNA7 copy number state using droplet digital PCR and genomic quantitative PCR. Demographic, anthropometric, and clinical data, including the Child Behavior Checklist (CBCL), were collected and compared across individuals with and without the CHRNA7 deletion.

resultsOf 218 individuals (90% males, mean age: 12.3 ± 2.3 years), 7 (3.2%) were found to carry a CHRNA7 deletion and one proband carried a CHRNA7 duplication (0.46%). T-scores for rule breaking, aggression, and externalizing behavior factors of the CBCL were higher in the deletion group, despite taking 58% higher dose of risperidone.

conclusionsCHRNA7 loss may contribute to a phenotype of severe aggression. Given the high prevalence of the deletion among risperidone-treated youth, future studies should examine the therapeutic potential of α7 nAChR-targeting drugs to target aggression associated with CHRNA7 deletions.

Indexed as

Gene DeletionAdolescentalpha7 Nicotinic Acetylcholine ReceptorAntipsychotic AgentsChildCohort StudiesFemaleHumansMaleNeurodevelopmental DisordersProspective StudiesRisperidoneTreatment Outcomealpha7 Nicotinic Acetylcholine ReceptorAntipsychotic AgentsChrna7 protein, humanRisperidone15q13.3 microdeletionaggressionCHRNA7disruptive behaviorsrisperidone

Identifiers

PMID28817303
PMCPMC5725633
OpenAlexW2745482835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.